Skip to content

EBIT at other companies

Doximity logo
DoximityDOCS
$24.83M-49.0%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$141.77M+41.3%
CVS Health logo
CVS HealthCVS
Amazon logo
AmazonAMZN
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
Cencora logo
CencoraCOR

Other financials

Income statement

See full
Revenue$194.0M-4.4%
Gross profit$173.9M-8.3%
Operating income$14.0M-40.1%
Net income$1.2M-89.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$235.7M-21.7%
Total debt$541.4M0.0%
Total equity$622.0M-4.9%
Total assets$2.0B+56.0%

Cash flow

See full
Operating cash flow$11.8M+25.8%
CapEx$1.1M+700%
Free cash flow$10.7M+15.4%

Valuation

See full
Market cap$934.74M-44.5%
Enterprise value$1.24B-35.4%
P/E45.5×-13.8×
P/S1.2×-0.9×

Profitability

See full
Gross margin91.8%-2.0pp
Operating margin9.9%-0.3pp
Net margin2.6%-1.0pp
FCF margin21%+2.3pp

Returns & leverage

See full
Return on equity3.2%-1.2pp
Debt / equity0.9×0.0×
Current ratio1.5×-3.8×

Where this comes from

Calculated from GoodRx Holdings, Inc.’s reported figures.

The official record: GoodRx Holdings, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about GoodRx Holdings, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GoodRx Holdings, Inc.'s EBIT?
GoodRx Holdings, Inc. (GDRX) reported EBIT of $14.01M in Q1 2026.
How has GoodRx Holdings, Inc.'s EBIT changed year-over-year?
GoodRx Holdings, Inc.'s EBIT decreased by 40.1% year-over-year, from $23.38M to $14.01M.
What is the long-term trend for GoodRx Holdings, Inc.'s EBIT?
Over 4 years (2021 to 2025), GoodRx Holdings, Inc.'s EBIT has grown at a 59.8% compound annual growth rate (CAGR), from $13.41M to $87.49M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.